SCR-LIP-000329 · Claim · machine-readable JSON →

This review proposes a mechanistic rationale for gestrinone in lipedema—based on aromatase overexpression in lipedema adipose tissue, with gestrinone hypothesized to inhibit aromatase and block estrogen receptors and adipogenesis—but presents only in vitro cell-viability data (MTT in MDA-MB-231 and Huh7 lines) and no clinical trial demonstrating efficacy in lipedema patients.

Created: 2026-05-31 · Last updated: 2026-05-31

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31

Evidence over time

Evidence (1)

• DOI:10.3390/ph17091248 — context · review · 2024
  The article is a narrative/mechanistic review that proposes gestrinone use in lipedema as a new application, offering a speculative aromatase-inhibition rationale and only in vitro cell data; it provides no clinical efficacy evidence in lip

Context (PECO)

Answers these questions

• Is gestrinone an effective treatment for lipedema? context

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log

• 2026-05-31 — created · auto-ingested for SQ-LIP-000016

← All claims